Pharmaceuticals & Biotech U.K. Community

Innovative niches in the market designed to tackle large problems. This company will be one to watch in the UK.Read more

Active Pipeline: HG-CT-1 - Hemogenyx CAR-T for R/R AML + expanding to pediatrics in H1 2025 targeting FLT3 which has recently been proven as an extremely promising and effective target. Significant interest in CAR-T treatments with each treatment 200k+, licensing deals in the range of 500m->1bn+ (including milestone payments) CDX - Building on same FLT3 target expands use of bi-specific antibody to a whole range of blood borne cancers and diseases including auto-immune.Read more

March Madness is here, or so they say on the basketball courts. But Marchs madness is slowly moving off to more than just the courts.Read more

Key Takeaways Rising regulatory costs and evolving health guidelines threaten margins, while core product reformulation may constrain long-term earnings and growth. Shifting consumer preferences and weak innovation expose Haleon to declining demand, competitive pressures, and limited ability to defend its leading brands.Read more

HUTCHMED is trying to turn its cancer drugs into a broader growth story by winning more treatment uses, pushing deeper into Japan and other markets, and rebuilding momentum in China after a tough stretch. The big question is whether new launches and its next wave of research can outweigh pricing pressure, regulation, and heavy reliance on just a few key medicines.Read more

GSK leans on fast-growing vaccines and newer specialty medicines, with a pipeline of potential launches that could keep the business growing even as older products face tougher competition. But patent cliffs, drug-pricing pushback, and lingering legal issues could squeeze cash and make it harder to deliver on that promise.Read more

PureTech Health’s business can look strong one year and weak the next because much of its money depends on partner milestones and drug sales royalties that don’t arrive on a steady schedule. The upside is that its “hub-and-spoke” pipeline could still pay off over time, but delays in outside funding, trial progress, or early sales performance could quickly change the picture.Read more

Shield Therapeutics bets heavily on one key iron-deficiency medicine, and growing competition plus tighter rules on drug pricing could make its path ahead bumpier than many expect. At the same time, rising prescriptions, new partners, and possible new uses and countries could keep demand growing—if access and pricing hold up.Read more

Oxford Biomedica is widening its manufacturing capabilities in cell and gene therapy, aiming to win more customer programs across the US and Europe while reducing reliance on any single technology. The upside is tied to growing demand and a push toward profitability, but costs, tariffs, and customer program setbacks could quickly derail momentum.Read more